drugset / Trial / NCT04173403
A Long-term Study of AK102 in Patients With Hypercholesterolemia
NaSingle-groupOpen-labelTreatment
Summary
This is a phase II, open-label, non-controlled, extended study. The main objective of this study is to evaluate the long-term efficacy and safety of AK102 in combination with basic lipid-lowering therapy in patients with hypercholesterolemia. Subjects who have participated in the AK102 studies and have completed the last visit,and who, in the opinion of the investigator, are likely to benefit from continued treatment will be enrolled in this study.
Timeline
- Start
- 2019-11-04
- Primary completion
- 2023-02-17
- Completion
- 2023-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AK102 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | AK102 | Monoclonal antibody | 450 mg | Subcutaneous |
| Background | Ezetimibe | Unknown | — | — |